TLDR:
- Cell BioEngines secures an additional $2 million in funding from SOSV and Empire State Development’s New York Ventures
- The funds will support the company’s first multicenter clinical trial for hematological cancer patients
Cell BioEngines, Inc., a New York-based company focused on researching stem cells for new cell therapies, recently secured $2 million in additional funding. The company received $1.75 million from SOSV and the Partnership Fund through the therapeutics seed track, as well as $0.25 million from Empire State Development’s NY Ventures. This funding will support the company’s upcoming multicenter clinical trial, which aims to provide alternative therapies for hematological cancer patients who cannot find a donor for HLA-haploidentical blood stem cell transplants.
Dr. Ajay Vishwakarma, the Founder and CEO of Cell BioEngines, expressed confidence in the company’s innovative approach to advancing cell therapies, noting that the investment reflects strong growth and investor confidence. The company’s leading therapy, CBE-101, utilizes expanded cord blood-derived hematopoietic cell therapy, aligning with their vision to deliver ‘off-the-shelf’ cell-based therapies to patients.
Cell BioEngines, Inc., founded in 2022, focuses on developing allogeneic ‘off-the-shelf’ stem cell-derived therapies for human disease treatment. The company uses proprietary platform technology to produce clinical grade cells at scale, obtained from umbilical cord blood stem cells. For more information about Cell BioEngines and their latest developments, visit their website at www.cellbioengines.com.
Contact: Mark Joubert., J.D., Chief Legal Officer, Cell BioEngines, Inc, email: info@cellbioengines.com
Tags: Cell Therapy
